BioToxTech Co

BioToxTech Co OCF Margin

The Operating Cash Flow Margin of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 14.11 %. In the previous year, Operating Cash Flow Margin was -17.22 % — a change of -181.95% (higher).

OCF Margin

14.11 %

YoY

-181.95%

Last updated:

Operating Cash Flow Margin of BioToxTech Co is 2025 14.11 % . Operating Cash Flow Margin of BioToxTech Co was 2024 -17.22 % . It decreases by -181.95% higher compared to the previous year.

The BioToxTech Co OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
11.24 KRW
Jan 1, 2019
5.58 KRW
Jan 1, 2020
17.27 KRW
Jan 1, 2021
13.28 KRW
Jan 1, 2022
-3.51 KRW
Jan 1, 2023
-49.76 KRW
Jan 1, 2024
-17.22 KRW
Jan 1, 2025
14.11 KRW
The BioToxTech Co OCF Margin history
YEAROCF MarginYoY
14.11 %-181.95%
-17.22 %-65.39%
-49.76 %+1,317.58%
-3.51 %-126.43%
13.28 %-23.07%
17.27 %+209.21%
5.58 %-50.30%
11.24 %-52.32%
23.56 %-0.73%
23.74 %-595.96%
-4.79 %-64.73%
-13.57 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Operating Cash Flow Margin of BioToxTech Co is 14.11 % in 2025.

Operating Cash Flow Margin of BioToxTech Co changed from -17.22 % to 14.11 %, representing a -181.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BioToxTech Co

All Key Metrics — BioToxTech Co